SEEK Awarded FP7 Grant to Fund Phase IIb Trial of Universal Flu Immunotherapeutic

London, UK, 15 October 2013: SEEK, a privately-owned UK pharmaceutical group, announces that it has been awarded a prestigious European Union Framework Programme 7 grant to advance the development of its universal flu immunotherapeutic, FLU-v.

http://www.biospace.com/news_story.aspx?StoryID=311823&full=1